Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo biomarcador del cáncer de mama

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20151022001
Publicado:
28/10/2015
Caducidad:
27/10/2016
Resumen:
Investigadores de una universidad inglesa han descubierto un nuevo patrón de fosforilación con alta correlación con la invasividad de células cancerosas. El test se basa en espectrometría de masas pero también puede desarrollarse un ensayo inmunológico. La técnica se aplica en biopsias simultáneamente con el triple test. La principal ventaja es que se evita la quimioterapia en pacientes que responden mal al tratamiento. Se buscan compañías biotecnológicas y farmacéuticas con el fin de establecer acuerdos de licencia.

Details

Tittle:
A new breast cancer biomarker
Summary:
Within the breast cancer sufferers group, the so-called triple negatives are offered chemotherapy. The test is still not very good so that many women get treated with no response.
Researchers at a university in the East of England have discovered a new phosphorylation pattern with high correlation to invasiveness and prognosis. The test is mass spectrometry based but an immunological assay can be developed.
Biotechnology or Pharma companies are sought for licensing.
Description:
Breast cancer affects 50,000 women per year in the UK and the incidence rate is even higher in several other of European countries.
The use of chemotherapy as treatment options for breast cancer is utilised within the population of breast cancer sufferers with tumours that are negative for receptors to oestrogen, progesterone and HER2. Upon biopsy the cancer´s receptors are identified to identify the best course of treatment. Within the triple negative population of breast cancer patients (15-20%), chemotherapy is offered as the treatment. Triple negative breast cancer is seen as a more invasive cancer with poor prognosis.
Although it´s a best practice, this triple test is not ideal as it is not the only possible marker to follow the progression and give a prognosis. A lot of women receive chemotherapy and still don´t respond to it.
Researchers at an East of England university have discovered a new marker to determine the best treatment option within triple negative breast cancer patients. This technology is based on a high resolution MS/MS technique where the phosphorylation pattern of certain residues within the C-terminal part of the tumour suppressor protein Scribble will enable a clinician to determine the best treatment option. The phosphorylation pattern on a cluster of sites in the C-terminal region of Scribble dramatically changes when cancer cells become more invasive. Loss of phosphorylation appears to be an early marker for invasion, metastatic propensity and ultimately poor prognosis. Whereas phosphorylation of the sites indicates a less invasive and less metastatic state of the cells. The current technology is mass spectrometry based and there is potential for an ELISA based method to be developed.
The technique will be applied on biopsies simultaneously with the triple test.
Biotechnology and Pharma companies are sought for licensing.
Advantages and Innovations:
The innovation lies in higher correlation between the phosphorylation pattern and the invasiveness of cancer cells.
The main advantage is the omission of unnecessary chemotherapy for poor responders.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent filed in the USA in October 2013.

Partner sought

Type and Role of Partner Sought:
Biotechnology and Pharma companies are sought for licensing.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis